Antimicrobial preservatives to achieve multi-dose formulation using betacyclodextrins for liquid dosage forms

Details for Australian Patent Application No. 2005216709 (hide)

Owner Pfizer Products Inc.

Inventors Wood, Julia Ann; David, Frederick; Adami, Roger Christopher

Agent Spruson & Ferguson

Pub. Number AU-B-2005216709

PCT Pub. Number WO2005/082416

Priority 60/540,897 30.01.04 US

Filing date 17 January 2005

Wipo publication date 9 September 2005

Acceptance publication date 7 February 2008

International Classifications

A61K 47/10 (2006.01) Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives - Alcohols

A61K 9/00 (2006.01) Medicinal preparations characterised by special physical form

A61K 47/00 (2006.01) Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives

A61K 47/40 (2006.01) Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives - Cyclodextrins

A61K 47/48 (2006.01) Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives - the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates

Event Publications

27 July 2006 PCT application entered the National Phase

  PCT publication WO2005/082416 Priority application(s): WO2005/082416

7 February 2008 Application Accepted

  Published as AU-B-2005216709

5 June 2008 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005216710-Therapeutic combinations

2005216707-Pharmaceutical compositions of neurokinin receptor antagonists and cyclodextrin and methods for improved injection site toleration